Glenmark's diabetes drug to enter phase lll trials

25 Jun 2009 Evaluate

Glenmark's novel molecule for diabetes- Melogliptin will now enter phase III trials. The phase II B trials have been successfully completed with the molecule achieving glycemic control with low incidence of hypoglycemia and neutral effect on body weight.

 

Global phase III trials have been planned with melogliptin and are due to start at the end of 2009 following regulatory approvals. These studies are designed to evaluate the compound both as monotherapy and in combination with other anti-diabetic therapies in patients with type 2 diabtes mellitus.

 

Glenmark continues to be in discussions with various licensing partners to take the molecule forward. The global diabetes markets is estimated at $24 bn in 2007 and projected to grow to $45 bn by 2018. It will likely be the leading drug class in metabolic and cardio vascular market. Oral anti-diabetics will drive the market growth with a projected share of 70 per cent of the total market.

crackcrack

Glenmark Pharma Share Price

1959.00 -15.15 (-0.77%)
05-Dec-2025 15:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1521.50
Zydus Lifesciences 933.10
Lupin 2089.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×